Superb Wisdom

Superb Wisdom is a clinical-stage biotechnology company based in China that specializes in the development of recombinant protein therapeutics. The company's primary focus is on the production of recombinant human serum albumin (rHSA) through advanced biotechnological expression systems, aiming to provide a safer, virus-free alternative to plasma-derived albumin. Its lead candidate is currently undergoing clinical trials for the treatment of hypoalbuminemia and complications related to liver cirrhosis, such as ascites. By leveraging large-scale fermentation and purification technologies, Superb Wisdom seeks to address the chronic global shortage of human albumin and improve patient outcomes in critical care and chronic liver disease management.